Shi-Yuan Cheng, PhD, professor in The Ken and Ruth Davee Department of Neurology in the Division of Neuro-oncology, has been named a fellow of the American Association for the Advancement of Science (AAAS) for his outstanding contributions to molecular and translational cancer research.
A new Northwestern Medicine study has identified tissue-specific epigenetic regulators in zebrafish, filling in a longtime gap in the understanding of the organism’s genome.
Combining the current standard-of-care chemotherapy drug with a genetic inhibitor may improve treatment for pancreatic ductal adenocarcinoma, according to a recent study published in PNAS.
A newly discovered function of an epigenetic regulator could be a key to new cancer treatments, according to a new study published in Genes and Development.
A brief course of immunotherapy resulted in complete and near complete remission in nearly two-thirds of previously untreated patients with classical Hodgkin lymphoma, according to a Northwestern Medicine trial.
A new three-dimensional imaging technique invented by Northwestern scientists greatly improves the visibility of brain tumors in magnetic resonance imaging scans.
Targeting the proteins CD47 and HER2 may eliminate radioresistant breast cancer cells and enable more effective radiotherapy treatments for patients, according to a new study.
The impact of COVID-19 on cancer patients has been a stark reality for many cancer centers around the world. For the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, a combination of time and dedication to patient care and research has resulted in the development of robust COVID-19 testing protocols to ensure the safety…
Treatment-resistant breast cancer could be made vulnerable to immunotherapy by flipping a metabolic “switch,” according to a new Northwestern Medicine study.
A new study found that Black men with metastatic prostate cancer were more likely to have tumor mutations than white or Asian men, highlighting the significance genetic drivers have in increasing one’s risk for developing aggressive prostate cancer.